Semaglutide reduces the risk of heart attack, stroke, and other major cardiac events. | Drug Discovery And Development ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

The Company’s investigational small moleculeglucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss ...

Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to the body of evidence supporting this potential treatment option.1 ...

Over 24% of Indian adults across all states are now considered overweight or obese with more than 12.5 million children under ...

New clinician-guided program blends medical science, microdosing, and 24/7 support to make advanced weight loss and wellness ...

SmartScripts has faced a welter of lawsuits and been fined for its sale of a counterfeit version of popular weight-loss drug Ozempic.

People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their ...

In a small study, patients who have successfully lost weight with weekly GLP-1 treatment maintain their weight loss and ...

A new international study has found that a diabetes pill called oral semaglutide can help protect the heart. This medication, ...

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and ...

Summary: Preclinical and clinical data support the continued development of ARD-201 to attenuate weight gain, promote weight loss, and help maintain weight after the discontinuation of glucagon-like ...